Abstract
Background Two pivotal phase 3 teriflunomide studies provided data on relapses, fatigue, and health-related quality of life (HRQoL) in patients with relapsing forms of multiple sclerosis (MS). Objectives Using pooled data from the TEMSO (NCT00134563) and TOWER (NCT00751881) studies, we investigated the association between relapse severity, and changes from baseline to Week 108 in fatigue and HRQoL outcomes. Methods Four definitions of relapse severity were applied in this analysis: sequelae post-relapse; relapse leading to hospitalization; relapse requiring intravenous corticosteroids; and intense relapse. We assessed the association between relapse severity and changes in Fatigue Impact Scale score (n=959), physical and mental health component summary scores from the Short Form (SF)-36 questionnaire (n=904), and SF-6D utility index scores (n=820). Results Irrespective of the definition of relapse severity applied, in patients experiencing severe relapse(s), fatigue was increased and HRQoL was decreased; these changes were statistically significant (p
Original language | English |
---|---|
Pages (from-to) | 33-40 |
Number of pages | 8 |
Journal | Multiple Sclerosis and Related Disorders |
Volume | 7 |
DOIs | |
Publication status | Published - May 1 2016 |
Keywords
- Fatigue
- FIS
- Multiple sclerosis
- Quality of life
- Relapse
- Sequelae
- SF-36
- Teriflunomide
ASJC Scopus subject areas
- Clinical Neurology
- Neurology